>
Date: Mon, 3 Mar 2003 18:25:04 -0500
X-Mailer: Microsoft Outlook IMO, Build 9.0.2416 (9.0.2911.0)
Dear Swiss Listers,
Please find below an announcement for a videoconferenced event between ETHZ
and SHARE. We will hear from three young entrepreneurs who started companies
right after graduation. This should also be an excellent occasion to listen
to a fast-moving Swiss entrepreneur, Joel Jean-Mairet and enjoy the expert
comments of the moderator, entrepreneur and professor, Les Charm.
Please send me a quick note if you intend to join us for this event!
-- Pascal
NOTE: if you want to see a graphic rich version of the invitation, please
visit our web site:
http://www.shareboston.org/events/events.html
INVITATION
Babson European Business Group, START and SHARE invite you to a
trans-Atlantic panel discussion and networking event:
**** The First 100 Days: Starting-up after Graduation ****
Moderator: Prof. Leslie Charm
Friday, March 7th
from 11:30 am to 1:30 pm at the Consulate of Switzerland, SHARE in
Cambridge.
Are you thinking about starting up right after graduation? Find out how US
and European entrepreneur alums from Babson, MIT and ETH Zurich did it, and
the effect that being in school had on their start-up plans and outcomes.
> Participants
Babson College:
Kirtland G. Poss, founder of VisEn Medical – www.visen.com
MIT:
Sonny Vu, founder of AgaMatrix – www.agamatrix.com
with his mentor Karl Ruping – www.incTANK.com
ETH Zürich:
Joel Jean-Mairet, founder of GlycART – www.glycart.com
> Program
The three entrepreneurs will each have 10 minutes to present their life
cases. The Swiss speaker and students from ETH Zurich will participate from
Switzerland via videoconference. Following the presentations will be a
discussion and question/answer period moderated by Professor Les Charm of
Babson College. The event will close with a networking reception for the
participants from Babson, MIT and other institutions. Snacks and Soda will
be provided.
> Logistics:
SHARE, located on 420 Broadway Street, is at the corner of Broadway and
Ellery Streets across from the Cambridge Library and Latin School. It is
about 10 minutes walking distance from both Harvard and Central Squares. For
directions to SHARE please visit: www.SHAREBoston.org.
Please contact us if you need transportation and RSVP by February 28th to
mschatt1_at_babson.edu to confirm your attendance.
> Background on the Speakers:
** Professor Leslie Charm:
Professor Charm has been a partner in the firm of Youngman & Charm since
1972. The firm specializes in directorship functions for firms owned and
operated by entrepreneurs and in assisting companies that are experiencing
operating and/or financial problems. Youngman & Charm has operated in a
variety of industries, channels of distribution, and has been involved in
many successful financings and acquisitions and mergers.
>From 1977 through 1990, Professor Charm was chairman and president of a
major distributor and specialty retail chain. He has been active in other
specialty marketing companies, and served as a member of the Board of
Directors of the International Franchise Association from 1983 to 1988. He
is currently director of the National Association of Corporate Directors-New
England, as well as director of several public and privately-held firms.
Professor Charm has taught throughout the world on a variety of topics
regarding entrepreneurship. He is on the President's Council at Babson, and
is the recipient of the Appel Award for Entrepreneurship. He is also a
Babson undergraduate alumnus.
** Kirtland G. Poss, President & CEO, VisEn Medical, Inc.:
· Prior to co-founding VisEn Medical, Inc., Kirtland G. Poss attended
the F.W. Olin School of Business at Babson College and also worked for
Boston Scientific Corporation in their Corporate Strategy group. Before
business school, Kirtland was a Manager at Kendall Strategies, a
business-strategy consulting firm focused exclusively on biomedical
companies. Earlier in his career, he developed his scientific expertise at
the Center for Molecular Imaging Research, where he worked with Dr. Ralph
Weissleder in developing novel MRI imaging agents and molecular drug
delivery systems.
· Optical imaging at the molecular level in vivo represents an entirely
new paradigm for the way diseases are identified and evaluated, and also how
their associated therapies are determined and managed. While current imaging
modalities are used primarily to image later stage disease morphologies,
VisEn Medical's proprietary optical imaging platforms now present a
breakthrough in the ability to image at the molecular level, both in animals
and in humans. These powerful technologies open the door to two
multi-billion dollar market opportunities: imaging of pharmaceutical
compound activity in animals for general research and pharmaceutical drug
development, and clinical molecular imaging of disease processes in humans.
VisEn`s technology platforms were developed at the Massachusetts General
Hospital and Harvard Medical School under Dr. Ralph Weissleder, Professor of
Radiology, Massachusetts General Hospital and Harvard Medical School,
Director of the Center for Molecular Imaging Research, MGH, and President of
The Society for Molecular Imaging(tm).
** Sonny Vu, Vice President, Business Development and Founder, AgaMatrix:
· Sonny brings management and entrepreneurial experience from having
worked in several of Microsoft's product groups and having launched and
built FireSpout, an enterprise software company. At Microsoft, he worked in
a number of product development groups, including the natural language group
responsible for shipping linguistic technologies to over 16 applications in
22 languages. While at FireSpout, Sonny created the original technology
vision, recruited the technical teams, managed the R & D efforts, and
developed the intellectual property strategy. Sonny was a Ph.D. candidate
at MIT prior to working in the software industry.
· AgaMatrix is a company based in Cambridge, MA that is commercializing
its proprietary biosensor chip technology, initially developed for the blood
glucose testing market, and which will be utilized for later applications in
other biochemical sensing segments. AgaMatrix has developed a DSP (digital
signal processing) technology to be used in biosensor-based devices that has
been shown to achieve a multiple-fold improvement in biosensor sensitivity,
accuracy and precision compared to existing products. This chip technology
will be licensed to existing medical diagnostic device makers to be embedded
in their next generation products. For the home testing market, we have
developed a lancet-based blood glucose system (diagnostic device and
proprietary test strip) that incorporates our biosensor chip technology and
is rated for alternative site testing. In addition to substantially improved
accuracy, the device requires a blood sample smaller than any other devices
on the market and is less painful to use.
** Karl Ruping, President, IncTANK:
· Karl is a Fellow at MIT’s Advanced Studies Program and a practicing
attorney/patent lawyer. With experience in Asia and Europe, his area of
specialization is software technologies and international protection of
intellectual property rights. Karl is president and founder of incTANK.
· IncTANK is an early stage venture capital firm with offices in Boston
and Tokyo. The main US office is located in the high-tech neighborhood of
Kendall Sq. between MIT and Harvard. IncTANK provides office space, support
staff, marketing expertise, legal services and venture funding to a select
number of portfolio companies with exciting technologies and global markets.
IncTANK Japan is located on the research campus of the University of Tokyo
where they work in cooperation with the technology licensing office, CASTI.
Their portfolio expends beyond the university to the Japan’s venture
business community in general.
** Joël Jean-Mairet, Chief Executive Officer, Member of the Board, GlycART:
· Joël Jean-Mairet is a co-founder of GLYCART biotechnology AG and
since its inception he has been the Chief Executive Officer. In parallel to
his PhD studies, he led GLYCART's business plan writing (in Top 10 of
McKinsey & Co.-ETH Venture 2000 business plan competition) and fund raising
efforts. For his achievements he received the New Entrepreneurs in
Technology and Science (NETS) prize 2001, which included an executive
program in the Babson College, US No.1 in Entrepreneurship. He also earned
for GLYCART the prestigious W.A. De Vigier prize, the highest innovation
award in Switzerland.
· GLYCART Biotechnology AG was founded in September 2000 by Joël
Jean-Mairet, Dr. Pablo Umaña, and Prof. Dr. James E. Bailey. The company is
a spin-off based on their research at the Swiss Federal Institute of
Technology Zurich (ETH). It is a privately held European company that is
active in the research, development and commercialization of new potent
antibody-based products for the treatment of unmet clinical needs such as
cancer. GLYCART's core platform technology -GlycoMAb - enhances the power of
monoclonal antibodies. GLYCART plans to develop high affinity antibodies
specific for strategically selected targets where GlycoMAb will maximize the
competitive advantage of such drugs and accelerate their development. The
company currently evaluating several validated targets within the fields of:
Angiogenesis, Adenocarcinomas, B-cell malignancies and autoimmune disorders.
=================================================================
To unsubscribe from the eastcoast mailing list send the
message body of "unsubscribe eastcoast" to majordomo_at_swiss-list.com
or visit http://www.swiss-list.com/mailings/
Received on Mon Mar 03 2003 - 22:58:28 PST
